Literature DB >> 27693863

Host response to Clostridium difficile infection: Diagnostics and detection.

Elena A Usacheva1, Jian-P Jin2, Lance R Peterson3.   

Abstract

Clostridium difficile infection (CDI) is a significant healthcare concern worldwide, and C. difficile is recognised as the most frequent aetiological agent of infectious healthcare-associated diarrhoea in hospitalised adult patients. The clinical manifestation of CDI varies from self-limited diarrhoea to life-threatening colitis. Such a broad disease spectrum can be explained by the impact of host factors. Currently, a complex CDI aetiology is widely accepted, acknowledging the interaction between bacteria and the host. C. difficile strains producing clostridial toxins A and B are considered toxigenic and can cause disease; those not producing the toxins are non-pathogenic. A person colonised with a toxigenic strain will not necessarily develop CDI. It is imperative to recognise patients with active disease from those only colonised with this pathogen and to implement appropriate treatment. This can be achieved by diagnostics that rely on host factors specific to CDI. This review will focus on major aspects of CDI pathogenesis and molecular mechanisms, describing host factors in disease progression and assessment of the host response in order to facilitate the development of CDI-specific diagnostics. Copyright Â
© 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; CDI; Clostridium difficile infection; Diagnostics; Host response; Pathogenesis

Mesh:

Year:  2016        PMID: 27693863      PMCID: PMC5124533          DOI: 10.1016/j.jgar.2016.08.002

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  110 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota.

Authors:  Vincent B Young; Thomas M Schmidt
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 3.  Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review.

Authors:  Tim Planche; Adamma Aghaizu; Richard Holliman; Peter Riley; Jan Poloniecki; Aodhán Breathnach; Sanjeev Krishna
Journal:  Lancet Infect Dis       Date:  2008-11-01       Impact factor: 25.071

4.  Evaluation of a rapid molecular screening approach for the detection of toxigenic Clostridium difficile in general and subsequent identification of the tcdC Δ117 mutation in human stools.

Authors:  R F de Boer; J J Wijma; T Schuurman; J Moedt; B G Dijk-Alberts; A Ott; A M D Kooistra-Smid; Y T H P van Duynhoven
Journal:  J Microbiol Methods       Date:  2010-07-30       Impact factor: 2.363

Review 5.  Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection.

Authors:  M H Wilcox
Journal:  Clin Microbiol Infect       Date:  2012-12       Impact factor: 8.067

Review 6.  Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections.

Authors:  C E Nord; L Kager; A Heimdahl
Journal:  Am J Med       Date:  1984-05-15       Impact factor: 4.965

7.  Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea.

Authors:  Yogesh M Shastri; Dominik Bergis; Nada Povse; Volker Schäfer; Sarika Shastri; Martin Weindel; Hans Ackermann; Jürgen Stein
Journal:  Am J Med       Date:  2008-12       Impact factor: 4.965

8.  Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.

Authors:  Glen P Carter; Anjana Chakravorty; Tu Anh Pham Nguyen; Steven Mileto; Fernanda Schreiber; Lucy Li; Pauline Howarth; Simon Clare; Bliss Cunningham; Susan P Sambol; Adam Cheknis; Iris Figueroa; Stuart Johnson; Dale Gerding; Julian I Rood; Gordon Dougan; Trevor D Lawley; Dena Lyras
Journal:  MBio       Date:  2015-06-02       Impact factor: 7.867

9.  Serum 25-Hydroxyvitamin D Levels are not Associated with Adverse Outcomes in Clostridium Difficile Infection.

Authors:  Dejan Micic; Krishna Rao; Bruno Caetano Trindade; Seth T Walk; Elizabeth Chenoweth; Ruchika Jain; Itishree Trivedi; Kavitha Santhosh; Vincent B Young; David M Aronoff
Journal:  Infect Dis Rep       Date:  2015-09-29

Review 10.  Clostridium difficile infection: a worldwide disease.

Authors:  Kristin E Burke; J Thomas Lamont
Journal:  Gut Liver       Date:  2014-01-13       Impact factor: 4.519

View more
  6 in total

1.  IL-17-producing γδ T cells protect against Clostridium difficile infection.

Authors:  Yee-Shiuan Chen; Iuan-Bor Chen; Giang Pham; Tzu-Yu Shao; Hansraj Bangar; Sing Sing Way; David B Haslam
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

2.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

3.  Probiotics Exhibit Strain-Specific Protective Effects in T84 Cells Challenged With Clostridioides difficile-Infected Fecal Water.

Authors:  Mohd Baasir Gaisawat; Silvia Lopez-Escalera; Chad W MacPherson; Michèle M Iskandar; Thomas A Tompkins; Stan Kubow
Journal:  Front Microbiol       Date:  2022-01-26       Impact factor: 5.640

4.  Loop mediated isothermal amplification of Clostridioides difficile isolates in gastrointestinal patients.

Authors:  Mojtaba Moosavian; Razieyeh Keshavarzi; Effat Abbasi Montazeri; Eskandar Hajiani
Journal:  AMB Express       Date:  2022-04-12       Impact factor: 3.298

5.  Fecal Host Transcriptomics for Non-Invasive Human Mucosal Immune Profiling: Proof of Concept in Clostridium Difficile Infection.

Authors:  Bert K Lopansri; Daniel T Leung; Robert Schlaberg; Amanda Barrett; Kornelia Edes; Michael Graves; Litty Paul; Jenna Rychert
Journal:  Pathog Immun       Date:  2018-09-12

6.  Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection.

Authors:  Elena A Usacheva; Lance R Peterson; Katherine Mendoza; Donna M Schora; M Moazzem Hossain; Jian-Ping Jin
Journal:  J Clin Med Res       Date:  2019-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.